Peter Pekos
Directeur/Membre du Conseil chez CARDIOL THERAPEUTICS INC.
Fortune : 859 814 $ au 30/04/2024
Postes actifs de Peter Pekos
Sociétés | Poste | Début | Fin |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Directeur/Membre du Conseil | 15/12/2017 | - |
Independent Dir/Board Member | 15/12/2017 | - | |
Dalton Chemical Laboratories, Inc.
Dalton Chemical Laboratories, Inc. Chemicals: Major DiversifiedProcess Industries Dalton Chemical Laboratories, Inc. engages in the provision of integrated drug discovery, development and manufacturing services. Its products include building blocks, glitazones, labelled compounds, natural compounds, peptides, steroids and controlled drugs. The firm also offers formulation development, flow chemistry, conjugation and contract research services. The company was founded by Peter Pekos in 1986 and is headquartered in Toronto, Canada. | Directeur Général | 01/01/1986 | - |
Fondateur | 01/01/1986 | - | |
President | 01/01/1986 | - | |
Biotechnology Focus | Corporate Officer/Principal | - | - |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Peter Pekos
Anciens postes connus de Peter Pekos
Sociétés | Poste | Début | Fin |
---|---|---|---|
Venturelab
Venturelab Miscellaneous Commercial ServicesCommercial Services ventureLAB provides business development solutions. Its programs focuses on capital, talent, technology, and customers. The company is headquartered in Markham, Canada. | Président | 01/01/2011 | 01/01/2020 |
Jupiter Consumer Products Ltd. | Fondateur | - | - |
Ashbury Biologicals, Inc. | Fondateur | - | - |
Formation de Peter Pekos
York University | Graduate Degree |
University of Toronto | Undergraduate Degree |
Statistiques
Internationale
Canada | 10 |
Opérationnelle
Founder | 3 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 3 |
Process Industries | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Dalton Chemical Laboratories, Inc.
Dalton Chemical Laboratories, Inc. Chemicals: Major DiversifiedProcess Industries Dalton Chemical Laboratories, Inc. engages in the provision of integrated drug discovery, development and manufacturing services. Its products include building blocks, glitazones, labelled compounds, natural compounds, peptides, steroids and controlled drugs. The firm also offers formulation development, flow chemistry, conjugation and contract research services. The company was founded by Peter Pekos in 1986 and is headquartered in Toronto, Canada. | Process Industries |
Ashbury Biologicals, Inc. | |
Jupiter Consumer Products Ltd. | |
Biotechnology Focus | |
Venturelab
Venturelab Miscellaneous Commercial ServicesCommercial Services ventureLAB provides business development solutions. Its programs focuses on capital, talent, technology, and customers. The company is headquartered in Markham, Canada. | Commercial Services |
Diamond Therapeutics, Inc.
Diamond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Diamond Therapeutics, Inc. is a Canadian clinical-stage drug development company founded in 2018 by Judy Blumstock. The company is based in an undisclosed location and is focused on developing safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. The company is developing sub-perceptual, non-hallucinogenic, psychedelic-based treatments that hold potential for use across a broad patient cohort, with the goal of maximizing the positive impact better drugs can have on the mental health crisis. Diamond's mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. | Health Technology |
- Bourse
- Insiders
- Peter Pekos
- Expérience